K-Ras G12C-IN-3

 CAS No.: 1629268-19-4  Cat No.: BP-300181  Purity: >98% 4.5  

K-Ras G12C-IN-3 is a mutant KRAS G12C ligand designed to engage the covalent pocket associated with the cysteine-containing mutant protein. This class of ligand provides a target-recognition element for exploring KRAS G12C-directed PROTAC or degrader-like strategies. In a bifunctional design, the KRAS G12C-binding moiety can be linked to an E3 ligase recruiter through an attachment site that preserves mutant-selective engagement while supporting proximity to ubiquitination machinery. The desired mechanism is ternary complex formation, mutant KRAS ubiquitination, and proteasome-dependent protein depletion. Such molecules can help researchers evaluate whether degradation of KRAS G12C produces signaling effects distinct from covalent pocket occupancy alone. K-Ras G12C-IN-3 is useful for mutant RAS chemical biology, degrader feasibility studies, linker optimization, target engagement assays, and development of selective tools for oncogenic KRAS pathway research.

K-Ras G12C-IN-3

Structure of 1629268-19-4

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
Ligand for Target Protein
Molecular Formula
C21H19Cl3N2O3
Molecular Weight
453.75

* For research and manufacturing use only. Not for human or clinical use.

SizePriceStockQuantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

  • Comprehensive PROTAC Platform
  • Scientific Expertise & Technical Support
  • Custom Synthesis & Design Service
  • Extensive Product Coverage
  • Cutting-Edge Innovation
  • Fast Delivery & Global Support
  • 24/7 customer service
  • 100% quality assurance
Popular Publications Citing BOC Sciences Products
Purity
>98%
Synonyms
K-Ras G12C-IN-3
InChI Key
RPBHAPLCWWQJAK-UHFFFAOYSA-N
InChI
InChI=1S/C21H19Cl3N2O3/c1-3-20(27)25-6-8-26(9-7-25)21(28)16-11-15(18(24)12-19(16)29-2)14-10-13(22)4-5-17(14)23/h3-5,10-12H,1,6-9H2,2H3
SMILES
COC1=C(C=C(C(=C1)Cl)C2=C(C=CC(=C2)Cl)Cl)C(=O)N3CCN(CC3)C(=O)C=C
Mechanism

Target: This ligand targets KRAS G12C mutant protein in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for KRAS G12C mutant protein. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings KRAS G12C mutant protein into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

Applications

• PROTAC-Mediated K-Ras Degradation: Use K-Ras G12C-IN-3 as a targeting ligand within PROTAC designs to recruit E3 ligases toward the G12C mutant state. This enables systematic evaluation of ternary complex formation, ubiquitination efficiency, and proteasome-dependent loss of K-Ras, supporting mechanism-of-action studies in Ras-driven signaling contexts.

• E3 Ligase Recruitment Optimization: Incorporate K-Ras G12C-IN-3 into PROTAC scaffolds to compare different E3 ligase recruiters and linker geometries. By tuning spatial orientation and binding kinetics, researchers can map degradation potency versus target engagement, identify effective ternary complex cooperativity, and optimize conditions for robust, selective degradation of G12C-bearing cells.

• Structure-Guided PROTAC Design: Apply structural and biophysical insights from K-Ras G12C-IN-3 binding to design PROTACs with improved compatibility at the mutant pocket. This direction supports rational linker placement, assessment of steric constraints, and refinement of binding modes to enhance ubiquitin transfer and accelerate proteolysis of K-Ras G12C.

• Pathway Suppression Mechanism Studies: Deploy K-Ras G12C-IN-3-based PROTACs to interrogate how selective degradation of mutant K-Ras reshapes downstream signaling. Researchers can correlate degradation kinetics and extent with changes in RAF/MEK/ERK and related pathways, distinguishing degradation-driven effects from occupancy-only outcomes and validating degradation specificity.

1.Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations.
Li J1, Wang S2, Su ZF2, Yuan Y2. Contemp Oncol (Pozn). 2016;20(1):33-8. doi: 10.5114/wo.2016.58499. Epub 2016 Mar 16.
K-ras is currently accepted as the most frequently mutated oncogene in non-small cell lung cancer (NSCLC, including squamous carcinoma, adenocarcinoma, and large cell carcinoma). NSCLC patients with the K-ras mutation appear to be refractory to the majority of systemic therapies. In the present study, the in vitro antitumor effects and correlated molecular mechanisms of sorafenib combined with gemcitabine or pemetrexed were explored in the K-ras mutation-positive NSCLC A549 cell line. Sorafenib was seen to exhibit dose-dependent growth inhibition in the A549 cells, while sorafenib combined with pemetrexed demonstrated a greater synergism compared with sorafenib combined with gemcitabine. Sorafenib arrested the cell cycle at the G1 phase, while gemcitabine and pemetrexed caused arrest at the S phase. The molecular mechanism of this synergism was due to the downstream signalling pathways, which were efficiently suppressed by sorafenib, therefore increasing the incidence of the entry of the chemotherapeutic drugs into the apoptotic pathways.
2.Geranylgeranyl Diphosphate Synthase Modulates Fetal Lung Branching Morphogenesis Possibly through Controlling K-Ras Prenylation.
Jia WJ1, Jiang S2, Tang QL2, Shen D2, Xue B2, Ning W3, Li CJ4. Am J Pathol. 2016 Apr 19. pii: S0002-9440(16)30024-4. doi: 10.1016/j.ajpath.2016.01.021. [Epub ahead of print]
G proteins play essential roles in regulating fetal lung development, and any defects in their expression or function (eg, activation or posttranslational modification) can lead to lung developmental malformation. Geranylgeranyl diphosphate synthase (GGPPS) can modulate protein prenylation that is required for protein membrane-anchoring and activation. Here, we report that GGPPS regulates fetal lung branching morphogenesis possibly through controlling K-Ras prenylation during fetal lung development. GGPPS was continuously expressed in lung epithelium throughout whole fetal lung development. Specific deletion of GGPS1 in lung epithelium during fetal lung development resulted in neonatal respiratory distress syndrome-like disease. The knockout mice died at postnatal day 1 of respiratory failure, and the lungs showed compensatory pneumonectasis, pulmonary atelectasis, and hyaline membranes. Subsequently, we proved that lung malformations in GGPS1-deficient mice resulted from the failure of fetal lung branching morphogenesis.
3.Equilibrium Thermodynamics and Kinetics of K-Ras Dimerization through an Effector Binding Surface.
Sayyed-Ahmed A, Gorfe AA. J Phys Chem B. 2016 Apr 12. [Epub ahead of print]
Dimer formation is believed to have a substantial impact on regulating K-Ras function. Yet the evidence for dimerization and the molecular details of the process are scant. In this study, we characterize a K-Ras pseudo-C2-symmetric dimerization interface involving the effector interacting β2-strand. We used structure matching and all-atom molecular dynamics (MD) simulations to predict, refine and investigate the stability of this interface. Our MD simulation revealed that β2-dimer is stable and remained relatively close to its initial conformation due to the presence of a number of hydrogen bonds, ionic salt bridges and other favorable contacts. Furthermore, we carried out potential of mean force calculations to determine the relative binding strength of the interface. The results of these calculations indicated that the β2 dimerization interface provides a weak binding free energy in solution and a dissociation constant close to 1 mM. In addition, analyses of Brownian dynamics simulations suggested an association rate of k_on ≈ 〖10〗^5-〖10〗^6 M^(-1) s^(-1).
4.Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
Ogawa M1, Anan T2, Suzuki T2, Okuma M2, Ichihara K2, Hasegawa T2, Yoshida K2, Yanaga K2. Anticancer Res. 2016 May;36(5):2505-11.
AIM: This prospective study was designed to evaluate the tolerability and the efficacy of bi-weekly SOX (S-1 and oxaliplatin)+cetuximab as first-line chemotherapy for wild-type K-RAS metastatic colorectal cancer.
ConcentrationVolumeMass1 mg5 mg10 mg
1 mM2.2039 mL11.0193 mL22.0386 mL
5 mM0.4408 mL2.2039 mL4.4077 mL
10 mM0.2204 mL1.1019 mL2.2039 mL

K-Ras G12C-IN-3 is a KRAS G12C ligand-like scaffold containing an acrylamide covalent warhead. It may support KRAS G12C-directed degrader design if the warhead remains accessible.

Structure: K-Ras G12C-IN-3 is a KRAS G12C ligand-like scaffold containing a dichlorinated biaryl region, methoxy substituent, piperazine carboxamide, and an acrylamide electrophilic warhead. The acrylamide is the key covalent-reactive feature, while the chlorinated aryl rings provide hydrophobic recognition elements.

Reactivity: For KRAS G12C-directed PROTAC design, the acrylamide warhead should be preserved and not used as the linker attachment point because it is required for covalent cysteine engagement. Linker installation should be explored from the piperazine or amide-associated vector in a designed analog. Alkyl, PEG, amide, carbamate, or piperazine-compatible linkers can be paired with CRBN, VHL, or IAP ligands while maintaining warhead accessibility and KRAS-binding orientation.

Can you provide the solubility of K-Ras G12C-IN-3 ?

Sure. The solubility of K-Ras G12C-IN-3 (CAS 1629268-19-4) in DMSO is ≥ 30 mg/mL (66.12 mM). This means that 30 milligrams of K-Ras G12C-IN-3 can be dissolved in 1 milliliter of DMSO.

9/11/2018

Do you know does K-Ras G12C-IN-3 biosynthesized monorhamnolipids?

No, K-Ras G12C-IN-3 does not biosynthesize monorhamnolipids.K-Ras G12C-IN-3 is a small molecule drug that is not produced by bacteria.

6/6/2019

Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g

Related Product Recommendations

BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
Germany
Inquiry Basket